Salbutamol, also known as albuterol and marketed as Ventolin among other brand names, is a medication that opens up the medium and large airways in the lungs. It is used to treat asthma, including asthma attacks, exercise-induced bronchoconstriction, and chronic obstructive pulmonary disease (COPD). It may also be used to treat high blood potassium levels. Salbutamol is usually used with an inhaler or nebulizer, but it is also available in a pill, liquid, and intravenous solution. Onset of action of the inhaled version is typically within 15 minutes and lasts for two to six hours.
(R)-(−)-salbutamol (center) and
|Trade names||Ventolin, Proventil, others|
|Synonyms||Albuterol (USAN US)|
|by mouth, inhalational, IV|
|Onset of action||<15 min (inhaled), <30 min (pill)|
|Elimination half-life||3.8–6 hours|
|Duration of action||2–6 hrs|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||239.311 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Common side effects include shakiness, headache, fast heart rate, dizziness, and feeling anxious. Serious side effects may include worsening bronchospasm, irregular heartbeat, and low blood potassium levels. It can be used during pregnancy and breastfeeding, but safety is not entirely clear. It is a short-acting β2 adrenergic receptor agonist which works by causing relaxation of airway smooth muscle.
Salbutamol was patented in 1966 in Britain and became commercially available in the UK in 1969. It was approved for medical use in the United States in 1982. It is on the World Health Organization's List of Essential Medicines, which lists the most effective and safe medicines needed in a health system. Salbutamol is available as a generic medication. The wholesale cost in the developing world of an inhaler which contains 200 doses is between US$1.12 and US$2.64 as of 2014. In the United States, it is between US$25 and US$50 for a typical month's supply. In 2016, it was the 10th most prescribed medication in the United States, with more than 47 million prescriptions.
Salbutamol is typically used to treat bronchospasm (due to any cause—allergic asthma or exercise-induced), as well as chronic obstructive pulmonary disease. It is also one of the most common medicines used in rescue inhalers (short-term bronchodilators to alleviate asthma attacks).
As a β2 agonist, salbutamol also has use in obstetrics. Intravenous salbutamol can be used as a tocolytic to relax the uterine smooth muscle to delay premature labor. While preferred over agents such as atosiban and ritodrine, its role has largely been replaced by the calcium channel blocker nifedipine, which is more effective and better tolerated.
The most common side effects are fine tremor, anxiety, headache, muscle cramps, dry mouth, and palpitation. Other symptoms may include tachycardia, arrhythmia, flushing of the skin, myocardial ischemia (rare), and disturbances of sleep and behaviour. Rarely occurring, but of importance, are allergic reactions of paradoxical bronchospasms, urticaria (hives), angioedema, hypotension, and collapse. High doses or prolonged use may cause hypokalemia, which is of concern especially in patients with renal failure and those on certain diuretics and xanthine derivatives.
The tertiary butyl group in salbutamol makes it more selective for β2 receptors, which are the predominant receptors on the bronchial smooth muscles. Activation of these receptors causes adenylyl cyclase to convert ATP to cAMP, beginning the signalling cascade that ends with the inhibition of myosin phosphorylation and lowering the intracellular concentration of calcium ions (myosin phosphorylation and calcium ions are necessary for muscle contractions). The increase in cAMP also inhibits inflammatory cells in the airway, such as basophils, eosinophils, and most especially mast cells, from releasing inflammatory mediators and cytokines. Salbutamol and other β2 receptor agonists also increase the conductance of channels sensitive to calcium and potassium ions, leading to hyperpolarization and relaxation of bronchial smooth muscles.
Salbutamol is either filtered out by the kidneys directly or is first metabolized into 4'-O-sulfate, which is excreted in the urine.
Structure and activityEdit
Salbutamol is sold as a racemic mixture. The (R)-(−)-enantiomer (CIP nomenclature) is shown in the image at right (top), and is responsible for the pharmacologic activity; the (S)-(+)-enantiomer (bottom) blocks metabolic pathways associated with elimination of itself and of the pharmacologically active enantiomer (R). The slower metabolism of the (S)-(+)-enantiomer also causes it to accumulate in the lungs, which can cause airway hyperreactivity and inflammation.
The 1972 Munich Olympics were the first Olympics where anti-doping measures were deployed, and at that time beta-2 agonists were considered to be stimulants with high risk of abuse for doping. Inhaled salbutamol was banned from those games, but by 1986 was permitted (although oral beta-2 agonists were not). After a steep rise in the number of athletes taking beta-2 agonists for asthma in the 1990s, Olympic athletes were required to provide proof that they had asthma in order be allowed to use inhaled beta-2 agonists.
Society and cultureEdit
The wholesale cost of a 200-dose inhaler is between US$1.12 and US$2.64 in the developing world as of 2014[update] and GB£1.50 in the United Kingdom as of 2015[update]. In the United States, a typical month's supply is between $25 and $50.
Salbutamol is the INN (international nonproprietary name) while albuterol is the USAN (United States adopted name). The drug is usually manufactured and distributed as the sulfate salt (salbutamol sulfate).
As of 2011[update] there was no evidence that an increase in physical performance occurs after inhaling salbutamol, but various reports for benefit when delivered orally or intravenously. In spite of this, salbutamol required "a declaration of Use in accordance with the International Standard for Therapeutic Use Exemptions" under the 2010 WADA prohibited list. This requirement was relaxed when the 2011 list was published to permit the use of "salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regimen."
Abuse of the drug may be confirmed by detection of its presence in plasma or urine, typically exceeding 1000 ng/mL. The window of detection for urine testing is on the order of just 24 hours, given the relatively short elimination half-life of the drug, estimated at between 5 and 6 hours following oral administration of 4 mg.
It has also been tested in a trial aimed at treatment of spinal muscular atrophy; it is speculated to modulate the alternative splicing of the SMN2 gene, increasing the amount of the SMN protein whose deficiency is regarded as a cause of the disease.
Salbutamol's low toxicity makes it safe for other animals and thus is the medication of choice for treating acute airway obstruction in most species. It is usually used to treat bronchospasm or coughs in cats and dogs and used as a bronchodilator in horses with recurrent airway obstruction; it can also be used in emergencies to treat asthmatic cats.
Toxic effects require an extremely high dose, and most overdoses are due to dogs chewing on and puncturing an inhaler or nebulizer vial.
- Thereaputic Goods Administration (2018-12-19). "Prescribing medicines in pregnancy database". Australian Government.
- "HSDB:Albuterol". ToxNet. US National Library of Medicine.
- "Salbutamol". Drugs.com. Archived from the original on 2016-03-30. Retrieved April 11, 2016. Cite uses deprecated parameter
- Thereaputic Goods Administration. "Poisons Standard October 2017". Australian Government.
- "Prescription Drug List". Government of Canada.
- "Albuterol". Drugs.com. The American Society of Health-System Pharmacists. Archived from the original on 2015-12-08. Retrieved Dec 2, 2015. Cite uses deprecated parameter
- Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM (April 2005). "Emergency interventions for hyperkalaemia". The Cochrane Database of Systematic Reviews (2): CD003235. doi:10.1002/14651858.CD003235.pub2. PMID 15846652.
- Starkey ES, Mulla H, Sammons HM, Pandya HC (September 2014). "Intravenous salbutamol for childhood asthma: evidence-based medicine?" (PDF). Archives of Disease in Childhood. 99 (9): 873–7. doi:10.1136/archdischild-2013-304467. PMID 24938536. Archived from the original (PDF) on 2017-09-08. Cite uses deprecated parameter
- Yaffe SJ (2011). Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk (9th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 32. ISBN 9781608317080. Archived from the original on 2015-12-08. Cite uses deprecated parameter
- Landau R (1999). Pharmaceutical innovation: revolutionizing human health. Philadelphia: Chemical Heritage Press. p. 226. ISBN 9780941901215. Archived from the original on 2015-12-08. Cite uses deprecated parameter
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 542. ISBN 9783527607495.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016. Cite uses deprecated parameter
- "Salbutamol". International Drug Price Indicator Guide. Retrieved 5 December 2015.
- Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 448. ISBN 9781284057560.
- "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
- Hatfield H. "Asthma: The Rescue Inhaler -- Now a Cornerstone of Asthma Treatment". WebMD. Archived from the original on 2017-07-16. Retrieved 2017-06-27. Cite uses deprecated parameter
- Rossi S (2004). Australian Medicines Handbook. AMH. ISBN 978-0-9578521-4-3.
- "126.96.36.199 Selective beta2 agonists – side effects". British National Formulary (57 ed.). London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society Publishing. March 2008. ISBN 978-0-85369-778-7.
- Lemke TL, Williams DA, Roche VF, Zito SW (2013). Foye's Principles of Medicinal Chemistry. Philadelphia, PA: Lippincott Williams & Wilkins. pp. 1314–1320. ISBN 9781609133450. OCLC 748675182. Archived from the original on 2017-09-08. Cite uses deprecated parameter
- "Albuterol Sulfate". Rx List: The Internet Drug Index. Archived from the original on 2014-07-18. Retrieved 2014-07-13. Cite uses deprecated parameter
- Papich MG (2007). "Albuterol Sulfate". Saunders Handbook of Veterinary Drugs (2nd ed.). St. Louis, Mo: Saunders/Elsevier. pp. 10–11. ISBN 9781416028888.
- US Department of Health and Human Services (2017-04-28). "Albuterol - Medical Countermeasures Database". CHEMM. Archived from the original on 2017-08-03. Retrieved 2017-06-23. Cite uses deprecated parameter
- Mehta A. "Medicinal Chemistry of the Peripheral Nervous System – Adrenergics and Cholinergics their Biosynthesis, Metabolism, and Structure Activity Relationships". Archived from the original on 2010-11-04. Retrieved 2010-10-20. Cite uses deprecated parameter
- "Inhalation Therapy of Airway Disease". Merck Veterinary Manual. Archived from the original on 2017-06-25. Retrieved 2017-06-22. Cite uses deprecated parameter
"Sir David Jack, who has died aged 87, was the scientific brain behind the rise of the pharmaceuticals company Glaxo". The Telegraph. Nov 17, 2011. Archived from the original on 2011-11-25. Cite uses deprecated parameter
- Fitch KD (2006). "beta2-Agonists at the Olympic Games". Clinical Reviews in Allergy & Immunology. 31 (2–3): 259–68. doi:10.1385/CRIAI:31:2:259. PMID 17085798.
- BNF 69: March 2015 - September 2015 (69 ed.). Pharmaceutical Pr. March 31, 2015. p. 190. ISBN 9780857111562.
- "Ventolin remains a breath of fresh air for asthma sufferers, after 40 years" (PDF). The Pharmaceutical Journal. 279 (7473): 404–405. Archived from the original (PDF) on October 15, 2007.
- Pluim BM, de Hon O, Staal JB, Limpens J, Kuipers H, Overbeek SE, et al. (January 2011). "β₂-Agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials". Sports Medicine. 41 (1): 39–57. doi:10.2165/11537540-000000000-00000. PMID 21142283.
- Davis E, Loiacono R, Summers RJ (June 2008). "The rush to adrenaline: drugs in sport acting on the beta-adrenergic system". British Journal of Pharmacology. 154 (3): 584–97. doi:10.1038/bjp.2008.164. PMC 2439523. PMID 18500380.
- "The 2010 Prohibited List International Standard" (PDF). WADA. Archived from the original (PDF) on 2013-09-11. Retrieved 2010-10-20. Cite uses deprecated parameter
- "The 2011 Prohibited List International Standard" (PDF). WADA. Archived (PDF) from the original on 2012-05-13. Retrieved 2012-05-22. Cite uses deprecated parameter
- Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Biomedical Publications. pp. 33–35. ISBN 978-0-9626523-6-3.
- Bergés R, Segura J, Ventura R, Fitch KD, Morton AR, Farré M, et al. (September 2000). "Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment". Clinical Chemistry. 46 (9): 1365–75. PMID 10973867. Archived from the original on 2011-07-17. Cite uses deprecated parameter
- Schweizer C, Saugy M, Kamber M (September 2004). "Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete". Clinical Journal of Sport Medicine. 14 (5): 312–5. doi:10.1097/00042752-200409000-00018. PMID 15377972. Archived from the original on 2012-10-05. Cite uses deprecated parameter
- Liewluck T, Selcen D, Engel AG (November 2011). "Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia". Muscle & Nerve. 44 (5): 789–94. doi:10.1002/mus.22176. PMC 3196786. PMID 21952943. Archived from the original on 2015-12-08. Cite uses deprecated parameter
- Van Meerbeke JP, Sumner CJ (October 2011). "Progress and promise: the current status of spinal muscular atrophy therapeutics". Discovery Medicine. 12 (65): 291–305. PMID 22031667.
- Lewelt A, Newcomb TM, Swoboda KJ (February 2012). "New therapeutic approaches to spinal muscular atrophy". Current Neurology and Neuroscience Reports. 12 (1): 42–53. doi:10.1007/s11910-011-0240-9. PMC 3260050. PMID 22134788.
- Plumb DC (2011). "Albuterol Sulfate". Plumb's Veterinary Drug Handbook (7th ed.). Stockholm, Wisconsin; Ames, Iowa: Wiley. pp. 24–25. ISBN 9780470959640.
- Clarke KW, Trim CM (2013-06-28). Veterinary Anaesthesia E-Book. Elsevier Health Sciences. p. 612. ISBN 9780702054235. Archived from the original on 2017-09-08. Cite uses deprecated parameter
- Cote E (2014-12-09). "Albuterol Toxicosis". Clinical Veterinary Advisor - E-Book: Dogs and Cats. Elsevier Health Sciences. pp. 45–46. ISBN 9780323240741. Archived from the original on 2017-09-08. Cite uses deprecated parameter